Tapering of Etanercept is feasible in patients with Rheumatoid Arthritis in sustained remission: a pragmatic randomized controlled trial

D Bertrand, V Stouten, D De Cock, S Pazmino, M Doumen, I de Wergifosse, J Joly, V Badot, L Corluy, I Hoffman, V Taelman, K De Knop, E Geens, C Langenaken, J L Lenaerts, J L Lenaerts, M Walschot, J Mannaerts, R Westhovens, P Verschueren

Onderzoeksoutput: Articlepeer review

4 Citaten (Scopus)


Objective: In patients with rheumatoid arthritis (RA) in sustained remission, tapering of biological disease-modifying anti-rheumatic drugs can be considered. Tapering has already been investigated, but its feasibility remains to be determined. Therefore, we explored the feasibility of tapering etanercept in RA in a setting close to practice.Method: Patients with RA in 28-joint Disease Activity Score (DAS28) remission (≥ 6 months) and treated with etanercept 50 mg weekly (≥ 1 year) were included in the pragmatic 1 year open-label multicentre randomized controlled TapERA (Tapering Etanercept in Rheumatoid Arthritis) trial. Patients were assigned to continue etanercept weekly or to taper to every other week (EOW). Patients who lost remission [DAS28-C-reactive protein (CRP) ≥ 2.6] were re-escalated to etanercept weekly. The primary outcome was the proportion of patients maintaining DAS28-CRP remission for 6 months.Results: Sixty-six patients were randomized to etanercept weekly (n = 34) or EOW (n = 32). After 6 months, 26/34 patients (76%) in the weekly and 19/32 (59%) in the EOW group maintained disease control (p = 0.136). In the EOW group, 20/32 patients (63%) remained on their tapered treatment during the trial. Two patients reintroduced weekly etanercept themselves. Ten patients were re-escalated to etanercept weekly by the rheumatologist, after a median (interquartile range) interval of 3.0 (2.0-6.0) months. Among these patients, 7/10 regained remission after re-escalation, four of them at the next study visit.Conclusions: Although non-inferiority could not be demonstrated, tapering of etanercept to EOW appeared feasible in patients in sustained remission.

Originele taal-2English
Pagina's (van-tot)470-480
Aantal pagina's11
TijdschriftScandinavian Journal of Rheumatology
Nummer van het tijdschrift6
Vroegere onlinedatum6 sep 2021
StatusPublished - 2 nov 2022

Bibliografische nota

Publisher Copyright:
© 2021 Scandinavian Journal of Rheumatology Foundation.

Copyright 2021 Elsevier B.V., All rights reserved.


Duik in de onderzoeksthema's van 'Tapering of Etanercept is feasible in patients with Rheumatoid Arthritis in sustained remission: a pragmatic randomized controlled trial'. Samen vormen ze een unieke vingerafdruk.

Citeer dit